Is Novo Nordisk A/S (NVO) Strengthening Its Weight-Loss Leadership With Oral Wegovy Launch?

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Novo Nordisk A/S (NYSE:NVO) is one of the best weight loss drugs on this list.

TheFly reported on June 16 that Berenberg increased its price target for NVO shares to DKK 325 from DKK 300 while maintaining its Buy rating on the stock.

Separately, on June 11, Novo Nordisk A/S (NYSE:NVO) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) approved the oral version of Wegovy for weight management in adults living with obesity or overweight individuals with at least one related health condition. The approval allows the Wegovy pill to be used alongside a reduced-calorie diet and increased physical activity, providing a new non-injectable option for patients seeking weight-loss treatment.

Is Novo Nordisk A/S (NVO) Strengthening Its Weight-Loss Leadership With Oral Wegovy Launch?

Khosro/Shutterstock.com

The daily oral glucagon-like peptide-1 (GLP-1) receptor agonist represents an alternative to injectable therapies currently used for obesity management. The MHRA decision was supported by results from the OASIS 4 Phase 3 clinical trial, which evaluated the effectiveness of the treatment. The approval expands NVO’s obesity treatment portfolio and introduces a more convenient delivery method for eligible patients.

Novo Nordisk A/S (NYSE:NVO) is a leader in the obesity treatment market, pioneering GLP-1 weight-loss drugs. Its portfolio includes Wegovy, oral semaglutide, and Ozempic, targeting obesity and cardiometabolic health while driving major growth in the global weight-management industry.

While we acknowledge the risk and potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NVO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1